Sutro Biopharma (STRO) Equity Ratio (2017 - 2025)

Sutro Biopharma's Equity Ratio history runs 9 years deep, the most recent figure standing at 0.76 for Q4 2025.

• In Q4 2025, Equity Ratio fell 761.5% year-over-year to 0.76; the TTM figure through Dec 2025 stood at 0.76 (down 761.5% YoY), while the FY2025 annual figure was 0.76, down 761.5% from the prior year.
• Equity Ratio came in at 0.76 for Q4 2025 at Sutro Biopharma, down from 0.42 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.86 in Q1 2021 to a low of 0.76 in Q4 2025.
• A 5-year average of 0.33 and a median of 0.33 in 2023 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio jumped 60.69% in 2021 and plunged 761.5% in 2025, its largest moves.
• Sutro Biopharma's Equity Ratio stood at 0.74 in 2021, then declined by 27.9% to 0.53 in 2022, then slumped by 40.4% to 0.32 in 2023, then plunged by 63.77% to 0.12 in 2024, then slumped by 761.5% to 0.76 in 2025.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.76, 0.42, and 0.12 for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison